Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

5.110 -0.140 (-2.74%)
Streaming Delayed Price 8:00:00 PM GMT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm
Via Benzinga
Recap: Verastem Q4 Earnings
  Verastem (NASDAQ:VSTM) reported its Q4 earnings results on Monday, March 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (... 
Via Benzinga
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
7 Cheap Biotech Stocks to Buy Now
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
From Verastem Oncology
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
51 Biggest Movers From Thursday
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of... 
Via Benzinga
Verastem Oncology's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q4, Verastem Oncology's (NASDAQ:VSTM) reported sales totaled $545.00 thousand. Despite a 27.67% increase in earnings, the company posted a loss of $16.48... 
Via Benzinga
Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development
Verastem Oncology Inc (NASDAQ: VSTM) entered into a credit facility with Oxford Finance LLC for  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
Upgrades 
Via Benzinga
Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors
From Verastem Oncology
Via Business Wire
Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board
From Verastem Oncology
Via Business Wire
Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why
Truist has initiated coverage on Verastem Oncology Inc (NASDAQ: VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2022
Upgrades Roth Capital upgraded the previous rating for Hudson Technologies Inc (NASDAQ:HDSN) from Neutral to Buy. For the fourth quarter, Hudson Technologies had an EPS of $0.13,... 
Via Benzinga
87 Biggest Movers From Yesterday
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 150% to close at $3.80 on Wednesday. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Surgalign Holdings (NASDAQ:SRGA) ... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Calyxt (NASDAQ:CLXT) shares rose 12.4% to $1.63 during Friday's pre-market session. The company's market cap stands at $62.7 million. Better Therapeutics (... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Enveric Biosciences (NASDAQ:ENVB)... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Anixa Biosciences (NASDAQ:ANIX) s... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.